Screening for Left Ventricular Systolic Dysfunction: Is Imaging a Solution?
John J. Atherton, MBBS, PhD*
Royal Brisbane and Women's Hospital and University of Queensland, Brisbane, Queensland, Australia
* Reprint requests and correspondence: Dr. John J. Atherton, Royal Brisbane and Women's Hospital, Butterfield Street, Herston, Queensland, QLD 4006 Australia (Email: john_atherton{at}health.qld.gov.au).
To address the heart failure burden, our focus needs to shift to disease prevention. Strategies to initially screen for heart failure precursors such as asymptomatic left ventricular systolic dysfunction have been evaluated, including clinical scores, the 12-lead electrocardiogram, and natriuretic peptides. However, their specificity limits their broad application as screening tools in asymptomatic populations. High-quality images are now available from hand-carried cardiac ultrasound devices, at a fraction of the capital cost of standard echocardiography with favorable diagnostic performance, especially when experienced staff perform the imaging. Questions that remain to be addressed include how we should select the target population to screen, who should perform the screening studies, how much training is required, and how often screening studies should be performed.
Key Words: diagnosis • heart failure • screening • ventricular dysfunction
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | ECG = electrocardiogram | | HCU = hand-carried cardiac ultrasound | | LV = left ventricular | | LVSD = left ventricular systolic dysfunction |
|
This article has been cited by other articles:
|
|
|
|
 
C. R. deFilippi, R. H. Christenson, W. J. Kop, J. S. Gottdiener, M. Zhan, and S. L. Seliger
Left Ventricular Ejection Fraction Assessment in Older Adults: An Adjunct to Natriuretic Peptide Testing to Identify Risk of New-Onset Heart Failure and Cardiovascular Death?
J. Am. Coll. Cardiol.,
September 27, 2011;
58(14):
1497 - 1506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
